Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Alpha-emitting radiopharmaceuticals
8 evidence topics · 4 sources
FDA-approved indication and dosing
Symptomatic bone-metastatic disease: trial population
Symptomatic bone-metastatic disease: overall survival versus placebo
| Analysis | Radium Ra 223 dichloride, median months (95% CI) | Placebo, median months (95% CI) | Hazard ratio (95% CI) |
|---|---|---|---|
| Interim analysis | “14.0 (12.1, 15.8)” | “11.2 (9.0, 13.2)” | “0.695 (0.552, 0.875)” |
| Updated analysis | “14.9 (13.9, 16.1)” | “11.3 (10.4, 12.8)” | “0.695 (0.581, 0.832)” |